Abstract: The present invention provides, among other things, polymeric reagents suitable for reaction with biologically active agents to form conjugates, the polymeric reagents comprising one or more polymer chains and a plurality of hydroxyapatite-targeting moieties, and optionally the reagents include one or more degradable linkages that serve to divide the polymer chains into polymer segments having a molecular weight suitable for renal clearance.

Abstract: This invention relates to thermoplastic elastomers comprising at least one silicone ionomer. These thermoplastic elastomers may be reprocessed and/or recycled.

Abstract: Pharmaceutical compositions of conjugates are provided. The conjugates can be prepared by (among other ways) conjugating a pharmacologically active agent with a polymeric reagent that has a particular arrangement of atoms. Related methods, preparations, and so forth are also provided.

Abstract: The present invention relates to biodegradable polymers (e.g., polyesters and polyester amides) derived from functionalized biologically active compounds that can provide site specific delivery of bioactive compounds upon biodegradation in a controlled manner.

Abstract: Amide compounds, amide polymers and compositions including amide compounds and amide polymers may be used to bind target ions, such as phosphorous-containing compounds in the gastrointestinal tract of animals. In some cases, the amide polymers may be amido-amine dendrimers that may be formed via a series of iterative reactions.

Abstract: Compositions are provided for promoting healing of tissue of a vertebrate organism. The compositions can be for internal administration of a therapeutically effective amount of pharmacologically active, protease inhibiting, aqueous media soluble polysulfonated materials in salt form and associated with a secondary material to reduce one or more of inflammation, bacterial proliferation, proteolytic activity, and cancerous cell growth. The compositions may additionally or alternatively be cross-linked so as to alter the solubility of these pharmacologically active salts or slow dissolution by providing biodegradable cross-linkers. Compositions for healing the tissue of a multicellular organism are provided that can include a polysulfonated material in a liquid mixture, as solid particles or constructs that may or may not biodegrade or deliver a pharmacologically relevant value.

Abstract: A biological coating material that includes a polymerizable polyacrylate monomer; a volatile liquid; a polymer selected from a synthetic rubber, a natural rubber, and a thermoplastic elastomer. The biological liquid coating material forms a coating or bandage in the form of a film that when applied and adhered to a surface or to the skin of a user inhibits the application surface from adhering to another surface.

Abstract: In one aspect, methods of promoting bone growth are described herein. In some embodiments, a method of promoting bone growth described herein comprises promoting cell differentiation or phenotype progression in a population of bone cells by providing a citrate-presenting composition to the population of bone cells. In some embodiments, the citrate-presenting composition is provided to the bone cells at a first stage of cell development selected to obtain a first cell differentiation or phenotype progression. Additionally, in some cases, a second citrate-presenting composition is further provided to the bone cells at a second stage of cell development selected to obtain a second cell differentiation or phenotype progression.

Abstract: Described are personal care compositions, comprising an aqueous dispersion comprising an ethylene acrylic acid copolymer and a least one cosmetically acceptable surfactant, emollient, or cosmetic active.

Abstract: Dendrimers comprising N-acyl urea terminal moieties are described herein. The dendrimers can be used, for example, in the treatment of arthritis.

Abstract: Provided is a composition for promoting ketone body production that comprises a water insoluble polymer of a ?-hydroxy short-medium chain fatty acid such as homopolymer of ?-hydroxybutyric acid or a copolymer of ?-hydroxybutyric acid and ?-hydroxyvaleric acid. The composition is useful for the treatment or prevention of a disease or condition that can be treated by promoting ketone body production.

Abstract: The methods and compositions disclosed herein are effective in the promoting the reattachment of delaminated cartilage to bone. The methods (and related compositions) comprise the removal of the acellular layer of the delaminated cartilage thereby exposing the underlying chondrocyte cells thereby allowing the promotion of the reattachment of the delaminated cartilage.

Abstract: The invention provides polymers that include a biologically active molecule and methods for their use.

Abstract: The invention consists of a rapidly crosslinkable, two-component silicone elastomer together with a specially designed tray that serves as a form for the silicone resin and forms an integral portion of a dental appliance.

Abstract: A tissue sealant that includes the reaction product of (a) a polyol; (b) a polyisocyanate; and (c) an alkoxy silane having the formula: (R1R2R3)—Si—CH2—Z where (i) Z is an —OH, —SH, —NCO, or —NHR4 group, where R4 is hydrogen, an alkyl group, or an aryl group; and (ii) each R1, R2, and R3, independently, is H, an alkoxy group, an alkyl group, a heteroalkyl group other than an alkoxy group, an aryl group, or a heteroaryl group, with the proviso that at least two of R1, R2, and R3 are alkoxy groups, the relative amounts of the polyol, polyisocyanate, and alkoxy silane being selected such that the reaction product comprises free isocyanate groups. The tissue sealant is moisture-curable and biodegradable in a physiological environment.

Abstract: The invention provides polymers and methods for their use. Specifically, certain embodiments of the present invention provide a polymer that comprises a plurality of salicylic acid-adipic (SA-Adipic) units of the following formula and a plurality of salicylic acid-diethylmalonic (SA-DEM) units of the following formula Certain embodiments of the invention also provide slow degrading microspheres comprising polymers described herein for undelayed and sustained drug delivery. Certain embodiments of the present invention provide methods for treating a chronic eye disease or arthritis in a patient, comprising administering to the patient a therapeutically effective amount of a polymer or microsphere as described herein.

Abstract: The present invention is directed to a composition containing: (a) at least one tackifier component having a glass transition temperature (Tg) of greater than about 20° C.; (b) at least one film former chosen from a propylphenylsilsesquioxane resin having a molecular weight of from about 2,000 to about 30,000 and comprising at least about 70 mole % propyl siloxy units and at most about 30 mole % phenyl siloxy units, and a propylsilsesquioxane wax substituted with alkyl units having at least 30 carbons; (c) a liquid fatty phase comprising at least one volatile hydrocarbon compound; (d) at least one colorant; (e) optionally, water; and (f) optionally, at least one emulsifier. Also disclosed is a method of making up keratinous substrates involving applying the above composition onto the keratinous substrates.

Abstract: A silicone surfactant-based synergistic agricultural formulation contains a combination of a first defined silicone surfactant and a second defined silicone surfactant in a concentration sufficient to cause a knockdown level on treated arthropods, even in the absence of known pesticidally active ingredients.

Abstract: The present invention provides compositions which not only effectively kill a broad spectrum of microorganisms present on surfaces on contact but continue to kill microorganisms for a period of time thereafter.

Abstract: An aqueous composition for treatment of water comprising: (a) an N,N-dimethyl-2-hydroxypropylammonium chloride polymer; (b) lanthanum chloride; and (c) a dimethylamine epichlorohydrin ethylenediamine polymer; and a method of treating water using the composition.

Abstract: A composition which can be detached from a surface which composition serves the purpose of impeding the detrimental effects of adherent fouling from the environment surrounding the surface. The composition may be single layered or multilayered as to allow for removal or attachment at multiple time points and/or over different durations. These time points may correspond to a progression to a negative effect of fouling, such as progression from biofilm maturation to bacterial detachment into host tissue for indwelling medical devices, or a predetermined threshold of tolerable fouling effect, such as blockage of a foley catheter by organic and inorganic encrustation material. This composition does not contribute to the function of the surface or the object whose boundaries are defined by the surface, such that its attachment or detachment is primarily aimed at mitigating the effects of fouling.

Abstract: The present invention relates to pregnancy hormone combinations and methods of treatment for autoimmune diseases having at least two hormonal components, a pregnancy hormone (such as estriol), and a gestagen (such as levonorgestrel or norethindrone) thereby providing for the continuous, uninterrupted administration of pregnancy hormones for the treatment for autoimmune disorders, such as multiple sclerosis.

Abstract: Tissue adhesives formed by reacting an oxidized polysaccharide with a water-dispersible multi-arm polyether amine, wherein at least three of the arms are terminated by primary amine groups, are disclosed. The use of the tissue adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; drug delivery; anti-adhesive applications; and as a bulking agent to treat urinary incontinence are described.

Abstract: The present invention relates in general to polymer-drug conjugates. In particular, the invention relates to polymer-drug conjugates wherein the conjugated drugs are selected from prostaglandins and substituted prostaglandins, to a method of delivering such prostaglandin drugs to a subject, to a sustained drug delivery system comprising the polymer-drug conjugates, to a method of preparing the polymer-drug conjugates, and to an implant comprising the polymer-drug conjugates. The polymer-drug conjugates may be useful for delivering prostaglandins and substituted prostaglandins for the treatment of glaucoma.

Abstract: Certain embodiments of the invention provide a copolymer having a backbone, wherein the backbone comprises a) one or more units that comprise a group that will yield a biologically active agent upon hydrolysis of the backbone; and b) one or more units of formula (II): wherein y is 1 or more. Other embodiments of the invention provide a therapeutic method for treating a wound in an animal comprising administering to an animal in need of such therapy, an effective amount of a copolymer as described herein.

Abstract: A method for repairing or replacing damaged tissue, or for providing post-surgical augmentation, comprising administering a pliable biocompatible material and a physiologically acceptable suspending agent to a patient is disclosed. Copolymers of unsubstituted acrylate and substituted acrylate are disclosed as pliable biocompatible materials.

Abstract: Embodiments of the invention include a system comprising: an Acetoxy curable silicone Binder; and an active agent blended with the silicone binder, effective for one or more of radiopacification, lubricity, elution of a secondary compound such as a drug, echogenic properties, thermal or electrically insulative properties or chemical indicators wherein the silicone binder effectiveness is not substantially changed by the active agent.

Abstract: Methods for soft tissue repair and/or augmentation using injectable, biodegradable polymers are described herein. In one embodiment, the polymer compositions are liquid or pastes at room temperature. In a preferred embodiment, the polymer composition contains liquid or pasty hydroxy fatty acid-based copolyesters, polyester-anhydrides, or combinations thereof. The viscosity of the polymers increases upon contact with bodily fluid to form a solid or semisolid implant suitable for soft tissue repair and/or augmentation. In another embodiment, the polymer composition contains particles of a polymer stereocomplex. One or more active agents may be incorporated into the polymer compositions. Suitable classes of active agents include local anesthetics, anti-inflammatory agents, antibiotics, analgesics, growth factors and agents that induce and/or enhance growth of tissue within the filled cavity or control the growth of a certain type of tissue, and combinations thereof.

Abstract: Provided herein re a composition and a coating or a device (e.g., absorbable stent) that includes a PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid biocompatible polymer and the methods of use thereof.

Abstract: Side-chain crystallizable (SCC) polymers are useful in various medical applications. In certain applications, heavy atom containing side-chain crystallizable polymers (HACSCCP's) are particularly useful. An example of a HACSCCP is a polymer that comprises a main chain, a plurality of crystallizable side chains, and a plurality of heavy atoms attached to the polymer. In certain configurations, the heavy atoms are present in an amount that is effective to render the polymer radiopaque. A polymeric material that includes an HACSCCP may be fabricated into a medical device useful for at least partially occluding a body cavity. For example, such a medical device may be an embolotherapy product. A polymeric material that includes a SCC polymer may also be fabricated into other medical devices, such as stents.

Abstract: A process for making cross-linked polysaccharide gels, particularly cross-linked hyaluronic acid gels, under basic conditions. The resulting gels possess improved degradation characteristics, and are useful in a variety of medical and cosmetic applications.

Abstract: The subject invention provides for methods of reducing the relapse rate and/or reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient, the method comprising orally administering to the patient a daily dose of 0.6 mg laquinimod. The subject invention also provides for pharmaceutical oral unit dosage forms of 0.6 mg laquinimod for use in reducing the relapse rate and/or for use in reducing the accumulation of physical disability in a relapsing-remitting multiple sclerosis human patient.

Abstract: Aniline copolymers and the synthesis thereof for use as antimicrobial (antibacterial, antifungal or antiviral material) material for the manufacture of antimicrobial objects, suitable for use in the health, food, packaging, water, paint, wood, textile, poultry, glass, paper, rubber, ceramic, seafood, sports, plastic and agricultural industries. The copolymer may be for example (A): where for example R3=H5—CO2H, —CO2Me, or CO2Et, R is typically H or a C1-C6 alkyl, x is an integer between 1 and 0 and m indicates the degree of polymerization. Preferred copolymers are copolymers of aniline with 3-aminobenzoic acid, 2-amonobenzoic acid and ethyl 3-aminobenzoate.

Abstract: The present invention relates to biodegradable polymers (e.g., polyesters and polyester amides) derived from functionalized biologically active compounds that can provide site specific delivery of bioactive compounds upon biodegradation in a controlled manner.

Abstract: In one aspect, methods for separating biological tissue are described herein. In some embodiments, a method for separating tissue comprises providing a first composition comprising a polymerizable material, providing a second composition comprising a polymerization initiator, disposing the first composition at a first site beneath a first tissue layer, disposing the second composition at the first site, polymerizing the polymerizable material at the first site, and separating the first tissue layer from a second tissue layer.

Abstract: Adhesives formed by reacting an oxidized polysaccharide with a poly(hydroxylic) compound derivatized with acetoacetate groups in the presence of a base catalyst are disclosed. The use of the adhesives for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; and drug delivery are described. The adhesive may also be used for industrial and consumer applications.

Abstract: Methods for sealing an orifice in tissue in the body of a living animal using an adhesive formed by reacting an oxidized polysaccharide with a poly(hydroxylic) compound derivatized with acetoacetate groups in the presence of a base catalyst are disclosed. Methods for using the adhesive for medical and veterinary applications such as topical wound closure; and surgical procedures, such as intestinal anastomosis, vascular anastomosis, tissue repair, and ophthalmic procedures; and drug delivery are described.

Abstract: The invention provides a means capable of effectively inactivating and removing allergen or a precursor thereof. The invention relates to an allergen-reducing agent containing water and a water-soluble polymer compound having units having hydroxy or carboxy groups wherein at least a part of hydrogen atoms of the hydroxy or carboxy groups are substituted by specific groups containing a polyether group.

Abstract: A method of forming a biocidal halogenated organic/inorganic composite material may include providing at least one inorganic precursor, providing at least one organic agent, precipitating an organic/inorganic composite material by contacting the at least one inorganic precursor with the at least one organic agent, and halogenating the organic/inorganic composite material by contacting the organic/inorganic composite material with a halogen. Also, a halogenated organic/inorganic composite material may include an inorganic composition comprising a metal oxide and a halogenated organic composition. The inorganic composition and the halogenated organic composition are dispersed throughout the composite material.

Abstract: The invention provides polymers and methods for the treatment of pain and inflammation.

Abstract: A medical antimicrobial composition includes a siloxanyl structure-containing polymer and an ammonium group-containing polymer, which is excellent in transparency, flexibility and mechanical properties, and also excellent in adhesion to a base resin with good mechanical properties, particularly to a silicone resin. The medical antimicrobial composition includes an ammonium group-containing polymer compound dispersed in a siloxanyl structure-containing polymer and a medical device comprising the medical antimicrobial composition.

Abstract: The invention provides a pharmaceutical composition for oral administration of a pharmaceutically active agent to a subject, including the pharmaceutically active agent and an inhibitor of CYP3A4. Administration of the inhibitor and the pharmaceutically active agent reduces pre-systemic degradation of the pharmaceutically active agent by CYP3A4. The inhibitor can be poly(ethylene glycol), methoxy poly(ethylene glycol), aminated poly(ethylene glycol), O-(2-aminoethyl)-O-methoxy poly(ethylene glycol), polyoxyethylene glycol, branched poly(ethylene glycol), 3-arm poly(ethylene glycol), 4-arm poly(ethylene glycol), 8-arm-poly(ethylene glycol)polyamine, poly(L-lysine), poly(L-arginine), poly(L-alanine), poly(L-valine), poly(L-serine), poly(L-histidine), poly(L-isoleucine), poly(L-leucine), poly(L-glutamic acid), poly(L-glutamine), poly(L-guanidine), poly(methyl methacrylate), polyvinyl acetate, polyacrylate, poly(lactic-co-glycolic acid) and derivatives thereof. A method of treatment is also described.

Abstract: Polymers, microspheres, and associated methods are presented for the treatment of chronic and acute pain. An anhydride polymer comprising a biodegradable backbone that comprises one or more pendant residues of a non-steroidal anti-inflammatory (NSAID). NSAIDs may be incorporated in to the polymers as pendant groups that are not part of the polymer backbone. The polymer comprises repeating units that form the biodegradable backbone, wherein in each repeating unit comprises a pendant residue of the NSAID.

Abstract: The present invention is directed to medical devices and pharmaceutical compositions containing a synthetic, bioabsorbable, biocompatible liquid polymer that is the reaction product of a polybasic acid or derivative thereof, a polyol and a fatty acid, the liquid polymer having a melting point less than about 40° C., as determined by differential scanning calorimetry.

Abstract: In one aspect, methods for separating biological tissue are described herein. In some embodiments, a method for separating tissue comprises providing a first composition comprising a polymerizable material, providing a second composition comprising a polymerization initiator, disposing the first composition at a first site beneath a first tissue layer, disposing the second composition at the first site, polymerizing the polymerizable material at the first site, and separating the first tissue layer from a second tissue layer.

Abstract: The present invention is directed to absorbable polyesters comprising one or more monophosphate functionality; a conjugate comprising the foregoing polyester and a peptide and/or a bioactive agent; microparticles comprising an absorbable polyester; a conjugate comprising the microparticles and a peptide and/or a bioactive agent; an acylated or alkylated polysaccharide having one or more monophosphate functionality; a conjugate comprising the acylated or alkylated polysaccharide and a peptide and/or a bioactive agent; and pharmaceutical compositions thereof.

Abstract: The present disclosure provides novel polyampholyte compounds, methods for synthesizing these compounds, and materials and substances incorporating these compounds. The various polyampholytes show antibacterial activity and may also demonstrate antiviral antifungal and/or antibiofilm activity.

Abstract: This invention relates to poly(ester amide)s (PEAs) comprising inactivated terminal amino and carboxyl groups, methods of synthesizing the inactivated PEAs and uses for them in the treatment of vascular diseases.

Abstract: The invention features polymers noncovalently complexed with a biologically active agent. The polymer complexes include at least one shielding moiety covalently tethered to at least one complexing moiety, which is complexed with at least one biologically active agent.

Abstract: A method of preparing a multiarm polymer includes reacting a branched polyol with one or more functionalizing reagents to effect substitution of an ionizable functional group or a protected ionizable functional group, Y, to form a mixture comprising (i) unsubstituted branched polyol containing no Y groups; (ii) a monosubstituted polyol comprising one Y group, and (iii) a multisubstituted polyol (e.g., a disubstituted polyol comprising two Y groups); followed by purifying the mixture to separate the monosubstituted polyol from other species Thereafter, a water-soluble and non-peptidic polymer segment is attached to the monosubstituted branched polyol at the site of at least one of the hydroxyl groups. The invention also provides purified monosubstituted branched polyols and multiarm polymers prepared by the method and polyol precursors for use in the method.